SLC5A2 and lung adenocarcinoma: A study showed that canagliflozin, an SGLT2 inhibitor, reduces tumor growth and enhances survival in a lung adenocarcinoma mouse model by inhibiting SGLT2 (Scafoglio et al., 2018).